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Summary.-Of 47 consecutive patients aged 15-60 years with acute non-myelo-
genous leukaemia (ANML) (40 acute lymphoblastic leukaemia (ALL);5acute Burkitt-
like leukaemia (ABLL), 2 acute undifferentiated leukaemia (AUL)) treated with a
standard chemotherapy protocol (OPAL), 31 achieved complete remission (28/40
(70%) of patients with ALL). CNS leukaemia occurred in 4/16 non-remitters, and
in 6 patients who achieved complete remission (CR). CNS leukaemia occurred in
all 5 patients with acute Burkitt-like leukaemia. 4/28 patients with ALL achieving
CR had evidence of CSF involvement on cytocentrifuge examination shortly after
CR. The apparent risk ofearly CNS disease suggests that prophylactic CNS therapy
should be given early in the treatment of acute non-myelogenous leukaemia.
EFFECTIVE TREATMENT has altered the
natural history of many malignancies.
This is well illustrated by the emergence
of central nervous system (CNS) disease
during prolonged remission of children
with acute lymphoblastic leukaemia
(ALL). Children developing leukaemic
infiltration ofthe CNS relapse systemically
earlier than those who do not. Pro-
phylactic therapy designed to prevent
such CNS relapse has led to a significant
improvement in survival and to possible
cures (Aur et al., 1972).
The results of treatment of adult ALL
are less satisfactory than those achieved
for childhood acute leukaemia, but none-
theless improvements in survival have
also been achieved (Clarkson et al., 1975).
On the basis of childhood studies, it
seems likely that prophylactic CNS treat-
ment will contribute to improved survival
in adult patients achieving complete re-
mission. The incidence of CNS involve-
ment in adult ALL has received less
attention than that in childhood. Analy-
sis is complicated by the fact that some
studies include both children and adults.
Nies, Thomas and Freireich (1965) com-
pared the incidence of meningeal leuk-
aemia in two series of patients with ALL,
the first diagnosed between 1953 and
1958 and the second between 1961 and
1963. The incidence of symptomatic
CNS disease was the same in both groups,
despite improved survivals in the latter
study. However, the overall incidence
of CNS involvement was 25% in the
first group and 42% in the second.
The difference was accounted for by the
detection of asymptomatic disease by
cerebro-spinal fluid (CSF) examination
in the second study. A real increase
in the incidence of CNS involvement in
association with prolonged survival is
suggested by Pavlovsky, Eppinger-Helft
and Muriel (1973) and Wolk et al. (1974).
Reprint requests to Dr. T. A. Lister, I.C.R.F. Department of Medical Oncology, St Bartholomew's
Hospital, London ECIA 7BE.T. A. LISTER kET AL.
Neither ofthese groupsroutinely examined
the CSF of asymptomatic patients, but
both used similar criteria for the recogni-
tion of involvement, namely the finding
of leukaemic blast cells in the CSF.
In Pavlovsky's study, the incidence of
CNS involvement appeared to increase to
19% at 20 months.
The finding by Simone et al. (1975)
that 1% of children have leukaemic
blast cells in the CSF, either at presenta-
tion or at the time of early CNS therapy,
suggests that a detailed study of patterns
of CNS disease in adult ALL may be
of value in determining the optimum
management which is required to prevent
CNS infiltration. A study of CNS disease
in patients with acute non-myelogenous
leukaemia between 15 and 60 years of
age has been carried out at St Bartholo-
mew's Hospital. This paper reports the
results of a 3-year study.
MATERIALS AND METHODS
Forty-seven consecutive adult patients
aged between 15 and 60 years with acute
non-myelogenous leukaemia (40 ALL; 5
acute Burkitt-like leukaemia (ABLL); 2
acute undifferentiated leukaemia (AUL))
admitted to St Bartholomew's Hospital
between November 1972 and June 1976
were treated with a standard protocol
(OPAL). The diagnosis was established by
examination of peripheral blood and bone
marrow aspirate smears. Acute non-myelo-
genous leukaemia was diagnosed when the
frequency of blasts in the bone marrow
exceeded 3000 and when these showed no
evidence of myeloid differentiation. Three
categories of acute non-myelogenous leuk-
aemia were recognized; ALL was identified
on the basis of infiltration with blast cells
of lymphoid appearance on Romanowsky
staining, which were Sudan Black negative
and some of which showed " block positive "
staining with the Periodic Acid-Schiff (PAS)
reaction. ABLL was recognized when the
infiltrating blastic cells had deeply baso-
philic vacuolated cytoplasm on the Roman-
owsky stain (Berard et al., 1969). These
were all negative with the PAS reaction.
A final category included those cases in
which the infiltrating cells were not morpho-
logically lymphoid or myeloid, and negative
with both Sudan Black and PAS (AUL).
OPAL protocol.-The combination of vin-
cristine and prednisolone, although highly
effective in childhood ALL, is less effective
in the adult variants. In consequence,
Erwinia asparaginase (Porton) (10,000 u/M2)
and prednisolone (40 mg) were given daily
for the first 14 days, and adriamycin (30
mg/M2) was given in a fast-running i.v.
infusion of normal saline plus vincristine
(2 mg) at weekly intervals. Injections of
vincristine and adriamycin were postponed
if there was cytopenia associated wvith
marrow hypoplasia. The marrow was
assessed 1 week after the fourth injection
of vincristine and adriamycin and, ifclinical
and haematological remission had not been
achieved, a further 2 injections were given
at weekly intervals and the marrow reassessed
1 week after the second. For a diagnosis
of complete remission there had to be
clinical, haematological and CNS freedom
from disease. The criteria laid down by
Hewlett et al. (1964) for peripheral blood
and bone marrow remission were used.
Remission was not recognized, however, if
abnormal blasts could be recognized in the
bone marrow, even if they constituted less
than 50o of the total nucleated count. All
patients achieving complete remission re-
ceived early CNS therapy, consisting of
crania] irradiation of 2400 rad (over 3 weeks)
and intrathecal methotrexate (12.5 mg twice
weekly for 5 doses).
CNS leuklaemia.-A cytocentrifuge pre-
paration of the CSF was examined in all
patients achieving clinical and haematolo-
gical remission, and a further 5 examinations
were made during intrathecal therapy. The
CSF of patients failing to achieve clinical
and haematological remission was only
studied if there was a clinical indication.
CSF examination was carried out within 1 h
of lumbar puncture; the smears were made
using the cytocentrifuge (Shandon). Ali-
quots (0.5 ml) of CSF were centrifuged in
duplicate at 1000 rev/min for 5 min. The
smears were dried and then stained by May-
Grunwald-Giemsa. Cytochemical stains
were also employed if appropriate, but in
practice these were not usually helpful
in deciding whether there was leukaemic
infiltration. Following examination of the
stained preparations, samples were cate-
gorized into " negative ", " infiltrated " or
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" infiltration suspected ". Infiltration was
diagnosed when there were at least 5 leuk-
aemic blast cells present in the cytocentri-
fuged deposit. The number 5 w%Aas chosen
on an empirical basis. Samples were clas-
sified as negative when no leukaemic blast
cells could be identified, even when the
total white count was otherwise raised.
Infiltration was suspected when an occasional
blast cell could be identified, but the total
of blast cells seen in the deposit was <5.
The appearance of cells in the deposit with
a high nuclear/cytoplasmic ratio and slightly
immature chromatin, frequently with ir-
regular and scanty cytoplasm, was also
regarded as suspicious of infiltration. Fol-
lowing treatment, CNS remission was ac-
cepted when 2 consecutive CSF deposits
were free from blast cells.
RESULTS
Forty-seven cases were treated using
the OPAL protocol and there were 31
complete remissions (details in Table I).
TABLE I.-Results of Remission Induction
in Acute Non-myelogenous Leukaemia
Diagnosis
ALL
ABLL*
ATILt
Total
40
5
2
Remission
28 (70%)
2
1
Non-remission
12
3
1
* Acute Burkitt-like leukaemia.
t Acute undifferentiated leukaemia.
CATS leukaemia in patients failing to
achieve clinical or haermatological remission
TABLE II.-CNS Leukaemia in
Non-remitters
Diagnosis
ALL
ABLL
AUL
Total Clinical (lisease CSF dlisease
12 1 0
3 :3 3
1 0 0
Sixteen patients receiving the OPAL
protocol failed to achieve complete re-
mission. One of the 12 cases of ALL
developed focal epilepsy in the presence
of retinal infiltrate. The platelet count
was normal and the epileptiform con-
vulsions were presumed to result from
leukaemic infiltration. All 3 cases of
ABLL failing to achieve clinical and
haematological remission developed cra-
nial nerve palsies. CSF examination re-
vealed blast cells, but in one of these
cases the CSF specimen was contaminated
with blood in which there were circulating
blast cells. Neither of the 2 cases of
AUL had clinical symptoms or signs
to suggest CNS infiltration, and routine
CSF examination was not carried out.
XCNS leukaemia inpatient achieving clinical
and haematological remission (Tables III
and IV)
There were 31 patients in this group.
Four out of 28 patients with ALL were
found to have definite blast cells in
the CSF, either on the first or on sub-
sequent CSF examinations during early
CNS therapy (Table III). A further 6
patients with ALL had suspicious cells
in the CSF during the same period
(Table IV). Since the significance of the
suspicious cells was uncertain, and might
have been related to intrathecal metho-
trexate, no further specific therapy was
TABLE III. CNS Leukaemia in Patients
with Clinical and Haematological Re-
mission
Type
ALL
ABLL
AUL
Total CSF-
28
2
1
18
0
0
CSF+ CSF±
4
0
6
0
1
TABLE IV.-Follow-up on Patients with
Suspicious Cells in the CSF at Clinical
and Haematological Remission
Diagnosis
1. ALL
2. ALL
3. ALL,
4. ALL
5. ALL
6. ALL
7. AUL
CSF 1 month
after end of
CNS therapy Further follow-up
Not (lone Lost
Continuing CR for 2
months
Continuing CR for 4
months
Continuing CR for 15
months
+ at 2nd haemato-
logical remission
Frequent CNS re-
lapses
Continuing CR for 21
months
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given. CSF examination was repeated
in 5 of the patients with a suspicious
CSF 1 month after therapy was com-
pleted. In 4 of these cases, the CSF
was clear, but in the fifth there was
infiltration which persisted to the time
of death. One of the 4 remaining pa-
tients has since relapsed, and examination
of the CSF at the time of his second
clinical remission revealed infiltration from
which he subsequently died. The 2 cases
ABLL had definite infiltration of the
CSF at the time of clinical and haemato-
logical remission (Table III) and the
1 case of acute undifferentiated leukaemia
had suspicious cells in the CSF throughout
the period of CNS therapy, but none at
the time of CSF examination 1 month
following completion of therapy (Table
IV).
DISCUSSION
This study reveals a high incidence
of early CNS leukaemia in adults with
ALL and ABLL (Table V). The appa-
TABLE V.-Overall Minimum Incidence of
CNS Leukaemia
Type
ALL
ABLL
AUL
Total
patients
40
5
2
Remitters
4/28
2/2
0
Non-
remitters
1/12
3/3
0
Overall
inci'dence
5/40
55
0Q2
rently low incidence of CNS leukaemia
in non-remitting patients with ALL (1/12)
may be accounted for by the fact that
routine CSF examinations were not carried
out. This possibility is emphasized by
the fact that of 28 patients with ALL
achieving clinical and haematological re-
mission a total of 4 were found to have
CNS leukaemia at diagnostic lumbar
puncture on the day of the complete
remission bone marrow. This is con-
siderably higher than the 10% incidence
of CNS leukaemia reported by Simone et
al. (1975) at complete remission of child-
hood ALL. The significance of suspicious
cells in the CSF is uncertain, since the
atypical appearance of the cells may
result from intrathecal therapy. How-
ever, of 6 patients reported to have
suspicious CSFs, 2 have subsequently
developed CNS leukaemia. For the pur-
poses of the trial, the report of suspicious
cells in the CSF was noted, but manage-
ment proceeded as though these patients
were in CNS remission. Subsequent CNS
relapse occurring in the remaining 4
patients would imply that the appearance
of suspicious cells in the CSF merits
management as though definite infiltra-
tion exists.
Symptomatic CNS disease developed
during the course of attempted remission
induction in the ABLL patients who
failed to achieve complete remission.
However, all cases (5/5) of ABLL de-
veloped CNS leukaemia during the course
of their illness. Those patienits who
achieved haematological and clinical com-
plete remission were found to have CNS
leukaemia at routine lumbar puncture
at the time haematological remission was
documented.
There is no doubt that early CNS
therapy is effective in preventing CNS
relapse and in prolonging complete re-
mission (Aur et al., 1972, 1973; M. R. C.,
1973; Muriel et al., 1974) provided therapy
is given before the advent of symptomatic
CNS involvement. Cranio-spinal irradia-
tion at the time of complete remission
has been compared with a group of
patients who received no such therapy,
by Aur et al. (1972). Only 2/45 of his
patients who received cranio-spinal irra-
diation relapsed, compared with 27/49
patients not receiving cranio-spinal the-
rapy. An important observation in this
study was that therapy designed to
eradicate the disease in the 27 patients
who relapsed in the CNS was unsatis-
factory.
Evidence is accumulating that there
is a strong case for starting CNS therapy
during remission induction in adults with
acute non-myelogenous leukaemia. This
is based on our finding of CNS disease
at the time of definitive clinical and
haematological remission, and the results
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of studies in childhood acute leukaemia
which suggest that prophylactic therapy
against CNS disease may contribute
towards prolonging disease-free survival
to the point of cure. Since the risks of
early involvement of the CNS in ABLL
appear to be very high indeed, remission
induction therapy should be planned to
allow CNS treatment from the outset.
This study has also indicated a significant
risk of CNS involvement early in the
management of ALL. Since intrathecal
therapy during remission induction may
prevent the emergence ofclinically evident
CNS involvement, we also advocate this
approach to the management of adult
ALL. The value of CNS therapy in
the management of patients with con-
sistently negative CSF examination should
become apparent from follow-up studies.
It is clear from this study that regular
cytological examination of the CSF plays
an important part in the management of
patients with adult acute non-myelo-
genous leukaemia. Until effective the-
rapy can bedeterminedforCNSleukaemia,
the proven advantage of prophylactic
therapy must be exploited to the full,
and in view of the apparent risk of the
early development of CNS disease it is
clear that this treatment should start
as early as possible during remission
induction in adult patients with acute
non-myelogenous leukaemia.
This study was carried out under
the direction of the late Professor Gordon
Hamilton Fairley, under whose care all
the patients were and to whom we are
all most grateful for all his advice and
support. We are also grateful to Dr
J. S. Malpas and Dr R. T. D. Oliver for
reading the manuscript.
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